Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same

摘要

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.

主权项

1. A method of treating a urinary tract disease in a mammalian subject in need thereof comprising:
(a) isolating skeletal muscle cells from a human; (b) cooling the skeletal muscle cells to a temperature lower than 10° C. and storing the cells for 1-7 days; (c) suspending the human skeletal muscle cells obtained in step (b) in a first cell culture container for between 30 and 120 minutes to which fibroblast cells of the cells from the skeletal muscle cell suspension adhere, wherein the remaining cells remain non-adherent; (d) decanting the medium from the first cell culture container to re-plate the non-adherent cells from step (c) in a second cell culture container, wherein the step of decanting is after 15-20% of cells have adhered to the first container; (e) allowing the non-adherent cells in the medium in the second cell culture container to attach to the walls of the second cell culture container; (f) repeating step (d)-(e) at least once, wherein the decanting is after 15-20% of cells have adhered to the wall of the previous cell culture container; (g) isolating the cells from the walls of the second cell culture container of step (e) or the container of step (f), wherein the isolated cells are skeletal muscle-derived progenitor cells (MDCs) and are desmin positive; and administering the MDCs to the urinary tract of the mammalian subject; thereby treating urinary tract disease in a mammalian subject in need thereof.